COVID-19 Resource Community

 View Only

Evusheld (Tixagevimab/cilgavimab) in TCT patients

  • 1.  Evusheld (Tixagevimab/cilgavimab) in TCT patients

    Posted 12-27-2022 04:07 PM
    Edited by shahram mori 12-27-2022 04:19 PM
    Looking at the TCT guidelines from August 2022.  Evusheld is recommended if the COVID variant is susceptible to the antibody. Given the minimal activity of Evusheld to the current dominant COVID clones, is there a benefit and do we have data for its benefit in transplant recipients? Thanks.

    Shahram Mori MD, PhD
    Sarah Cannon Transplant and Cellular Therapy